1438413-72-9

Upstream product

• 127094-57-9 4,6-dichloro-(1,5)-naphthyridine-3-carboxylic acid ethyl ester 
• 1416000-52-6 ethyl 6-chloro-4-((3-(trifluoromethyl)phenyl)amino)-1,5-naphthyridine-3-carboxylate 
• 4487-59-6 2-bromo-5-nitropyridine 
• 13534-97-9 6-bromopyridine-3-amine 
• 1220700-73-1 diethyl 2-(((6-bromopyridin-3-yl)amino)methylene)malonate 
• 1184919-05-8 ethyl 6-bromo-4-hydroxy-1,5-naphthyridine-3-carboxylate 

Downstream Products

• 1416000-54-8 6-chloro-4-((3-(trifluoromethyl)phenyl)amino)-1,5-naphthyridine-3-carbaldehyde 
• 1416000-57-1 2-chloro-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5]naphthyridin-9(10H)-one 
• 1415999-92-6 N-(5-(9-oxo-10-(3-(trifluoromethyl)phenyl)-9,10-dihydropyrido[3,2-c][1,5]naphthyridin-2-yl) pyridin-2-yl)acetamide 
• 1416000-85-5 tert-butyl 3-(9-oxo-10-(3-(trifluoromethyl)phenyl)-9,10-dihydropyrido[3,2-c][1,5]naphthyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-1-carboxylate 
• 1415999-96-0 2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 
• 1415999-98-2 2-(6-(hydroxymethyl)pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 
• 1416000-00-4 2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 
• 1416000-02-6 2-(6-(1H-pyrazol-1-yl)pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 
• 1416000-08-2 2-(6-(methylsulfonyl)pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 
• 1416000-28-6 10-(3-(trifluoromethyl)phenyl)-2-(5-(trifluoromethyl)pyridin-3-yl)pyrido[3,2-c][1,5]naphthyridin-9(10H)-one 
• 1416000-33-3 3-methyl-5-(9-oxo-10-(3-(trifluoromethyl) phenyl)-9,10-dihydropyrido[3,2-c][1,5] naphthyridin-2-yl)-2-cyanopyridine 

Relevant academic research and scientific papers

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite

This study presents a process of developing a novel PI3K-mTOR inhibitor through the prodrug of a metabolite. The lead compound (compound 1) was identified with similar efficacy as that of NVP-BEZ235 in a tumor xenograft model, but the exposure of compound

THREE-RING PI3K AND/OR MTOR INHIBITOR

The present application relates to a compound as represented by general formula (I), a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, preparation method of the compounds, a pharmaceutical composition containing the compounds, us

PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

THREE-RING PI3K AND/OR MTOR INHIBITOR

The present application relates to a compound as represented by general formula (I), a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, preparation method of the compounds, a pharmaceutical composition containing the compounds, uses thereof in the preparation of drugs for treating and/or preventing proliferative diseases, and a method using the compounds to treat and/or prevent proliferative diseases. R1, R2, R3, R4, R5, R6, X, A and B in the formula are as defined in the specification.